Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats

Anti-Cancer Drugs

Volumn 20, Issue 7, 2009, Pages 584-588

  Shin, Sang Chul ^a   Choi, Jun Shik ^b  

^a Chonnam National University   (South Korea)

^b Chosun University   (South Korea)

Author keywords

Bioavailability; Epigallocatechin gallate; Pharmacokinetics; Rats; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; CYTOCHROME P450 3A; EPIGALLOCATECHIN GALLATE; GLYCOPROTEIN P; TAMOXIFEN; 4-HYDROXYTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CATECHIN; DRUG DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; FIRST PASS EFFECT; INTESTINE; LIVER; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL; BIOAVAILABILITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CATECHIN; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; INJECTIONS, INTRAVENOUS; INTESTINES; LIVER; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 70149095905     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832d6834     Document Type: Article

References (36)

1. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995; 13:513-529.
2. Buckley MT, Goa KL. Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Clin Pharmacokin 1989; 37:451-490.
3. Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen, I. Cytochrome P450-catalysed N-demethylation and 4-hydroxylation. Drug Metab Dispos 1993; 21:645-656. (Pubitemid 23221760)
4. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997; 53:171-178.
5. Borgna JL, Rochefort H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J Biol Chem 1981; 256:859-868.
6. Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res 1982; 42:317-323.
7. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95:1758-1764.
8. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85:151-159.
9. Rao US, Fine RL, Scarborough GA. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 1994; 48:287-292.
10. Gant TW, O'Connor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995; 133:269-276.
11. Sutherland L, Ebner T, Burchell B. The expression of UDP- glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 1993; 45:295-301.
12. Turgeon D, Carrier JS, Levesque E, Hum DW, Bélanger A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001; 142:778-787.
13. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13:129-134.
14. Dixon RA, Steel CL. Flavonoids and isoflavonoids-a gold mine for metabolic engineering. Trend Plant Sci 1999; 4:394-400.
15. Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 2001; 74:418-425.
16. Chu DC, Juneja LR. Chemistry and applications of green tea. In: Yamamoto T, Juneja LR, Chu DC, Kim M, editors. New York: CRC Press; 1997. pp. 13-22.
17. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant function. Crit Rev Food Sic Nutr 2003; 43:89-143.
18. Kuroda Y, Hara Y. Antimutagenic and anticarcinogenic activity of tea polyphenols. Mutat Res 1999; 436:69-97.
19. Muto S, Fujita K, Yamazaki Y, Kamataki T. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat Res 2001; 479:197-206.
20. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 2002; 1542:149-159.
21. Kitagawa S, Nabekura T, Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 2004; 56:1001-1005.
22. Lin LC, Wang MN, Tseng TY, Sung JS, Tsai TH. Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J Agric Food Chem 2007; 55:1517-1524.
23. Henning SM, Niu Y, Liu Y, Lee NH, Hara Y, Thames GD, et al. Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 2005; 16:610-616.
24. Ullmann U, Haller J, Bakker GC, Brink EJ, Weber P. Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man. Phytomedicine 2005; 12:410-415.
25. Lemos C, Peters GJ, Jansen G, Martel F, Calhau C. Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds. Eur J Nutr 2007; 46:329-336.
26. Freid KM, Wainer IW. Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatography. J Chromatog B Biomed Appl 1994; 655:261-268.
27. Li C, Choi JS. Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats. Pharmazie 2008; 63:815-818.
28. Chung JH, Choi DH, Choi JS. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos 2009; 30:90-93.
29. Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 2006; 313:144-149.
30. Shin SC, Piao YJ, Choi JS. Effects of morin on the bioavailability of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rat. In Vivo 2008; 22:391-395.
31. Piao YJ, Shin SC, Choi JS. Effects of oral kaempferol on the pharmacokinetics of tamoxifen and one of its metabolites, 4-hydroxytamoxifen, after oral administration of tamoxifen to rats. Biopharm Drug Dispos 2008; 29:245-249.
32. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.
33. Lefebvre M, Homsy W, Caille G, du Souich P. First-pass metabolism of diltiazem in anesthetized rabbits: role of extrahepatic organs. Pharm Res 1996; 13:124-128.
34. Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW, Thakker DR. CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 1996; 24:344-349.
35. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87:1322-1330.
36. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1996; 27:161-170.